MAB8508
antibody from Abnova Corporation
Targeting: ABRAXAS1
ABRA1, ABRAXAS, CCDC98, FAM175A, FLJ13614
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB8508 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#MAB8508, RRID:AB_10721494
- Product name
- FAM175A monoclonal antibody, clone ABRA1-01
- Antibody type
- Monoclonal
- Description
- Mouse monoclonal antibody raised against partial recombinant FAM175A.
- Isotype
- IgG
- Antibody clone number
- ABRA1-01
- Storage
- Store at 4°C. Do not freeze.
Submitted references Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function.
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage.
CCDC98 targets BRCA1 to DNA damage sites.
Nikkilä J, Coleman KA, Morrissey D, Pylkäs K, Erkko H, Messick TE, Karppinen SM, Amelina A, Winqvist R, Greenberg RA
Oncogene 2009 Apr 23;28(16):1843-52
Oncogene 2009 Apr 23;28(16):1843-52
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP, Elledge SJ
Science (New York, N.Y.) 2007 May 25;316(5828):1194-8
Science (New York, N.Y.) 2007 May 25;316(5828):1194-8
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage.
Wang B, Elledge SJ
Proceedings of the National Academy of Sciences of the United States of America 2007 Dec 26;104(52):20759-63
Proceedings of the National Academy of Sciences of the United States of America 2007 Dec 26;104(52):20759-63
CCDC98 targets BRCA1 to DNA damage sites.
Liu Z, Wu J, Yu X
Nature structural & molecular biology 2007 Aug;14(8):716-20
Nature structural & molecular biology 2007 Aug;14(8):716-20
No comments: Submit comment
No validations: Submit validation data